Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. This move expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
The Epi+Gen CHD test evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.
This coverage is significant because it brings advanced, AI-driven cardiovascular testing to a broader patient population within managed care settings. By integrating these tests into Atlas Healthcare Physicians’ network, Cardio Diagnostics aims to improve early detection and personalized management of coronary heart disease, potentially reducing the burden of cardiovascular events. The tests leverage a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, which analyzes genetic and epigenetic markers to provide personalized risk assessments and diagnostic insights.
For patients, this means easier access to cutting-edge diagnostics that can inform treatment decisions without the need for invasive procedures or radiation. For the healthcare system, broader use of precision medicine tools could lead to more efficient resource allocation and better patient outcomes. The expansion also underscores the growing role of AI in cardiovascular care, as Cardio Diagnostics continues to commercialize its technology.
The full press release is available at https://nnw.fm/EFQen. For more information about Cardio Diagnostics and its latest updates, visit the company’s newsroom at https://ibn.fm/CDIO.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company’s filings with the SEC. Undue reliance should not be placed on such statements, which are based on information available as of the date hereof.
